Psychiatric disorders are among the top causes of disability and morbidity worldwide. Despite the rapid progression of psychiatric pharmaceuticals, there are still significant challenges for the effective management of psychiatric disorders. The blood–brain barrier significantly restricts the access of psychiatric drugs to target cells in the brain tissues. The use of drug-loaded nanoparticles (NPs) is now well considered a viable option for improving the treatment efficacy of currently available drugs and reducing adverse effects. This review summarizes the recent advances and provides the unique characteristics of NP-based formulations as a promising avenue for targeted drug delivery for psychiatric disorders.
Cite this article as: Shafiee-Kandjani AR, Hamidi S, Azarfarin M, Valipour F, Salatin S. Nano-assisted drug delivery systems for the improved treatment of neuropsychiatric disorders. Neuropsychiatr Invest. 2025, 63, 0058, doi: 10.5152/NeuropsychiatricInvest.2025.24058.